YU46196A - (1s,2s)-1-(4-hidroksifenil)-2-(4-dihidroksi-4-fenilpiperidin 1-il)-1-propanol metansul-fonat trihidrat - Google Patents

(1s,2s)-1-(4-hidroksifenil)-2-(4-dihidroksi-4-fenilpiperidin 1-il)-1-propanol metansul-fonat trihidrat

Info

Publication number
YU46196A
YU46196A YU46196A YU46196A YU46196A YU 46196 A YU46196 A YU 46196A YU 46196 A YU46196 A YU 46196A YU 46196 A YU46196 A YU 46196A YU 46196 A YU46196 A YU 46196A
Authority
YU
Yugoslavia
Prior art keywords
trihydrate
dihidroxy
hidroxy
propanole
phenylpiperidine
Prior art date
Application number
YU46196A
Other languages
English (en)
Inventor
Marta Maria Andino
Terry Gene Sinay
Eugene Fred Fiese
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU46196A publication Critical patent/YU46196A/sh
Publication of RS49521B publication Critical patent/RS49521B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Ovaj pronalazak odnosi se na trihidrat mezilatne soli (1S,2S)-1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola, na farmaceutske smese koje ga sadrže i na postupke za njegovu upotrebu za tretiranje poremećaja CNS.
YU46196A 1995-08-11 1996-08-09 (1s, 2s)-1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol metansulfonat trihidrat RS49521B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11

Publications (2)

Publication Number Publication Date
YU46196A true YU46196A (sh) 1999-07-28
RS49521B RS49521B (sr) 2006-10-27

Family

ID=21699847

Country Status (41)

Country Link
US (1) US6008233A (sh)
EP (1) EP0843661B1 (sh)
JP (1) JP3099072B2 (sh)
KR (1) KR100291882B1 (sh)
CN (2) CN1198739A (sh)
AP (1) AP755A (sh)
AR (1) AR004676A1 (sh)
AT (1) ATE215072T1 (sh)
AU (1) AU710984B2 (sh)
BG (1) BG63678B1 (sh)
BR (1) BR9610766A (sh)
CA (1) CA2228752C (sh)
CO (1) CO4750830A1 (sh)
CZ (1) CZ296236B6 (sh)
DE (1) DE69620191T2 (sh)
DK (1) DK0843661T3 (sh)
DZ (1) DZ2083A1 (sh)
ES (1) ES2170857T3 (sh)
GT (1) GT199600051A (sh)
HR (1) HRP960372B1 (sh)
HU (1) HUP9802862A3 (sh)
IL (1) IL122649A (sh)
IS (1) IS1945B (sh)
MA (1) MA23957A1 (sh)
NO (1) NO310458B1 (sh)
NZ (1) NZ309134A (sh)
OA (1) OA10664A (sh)
PE (1) PE4898A1 (sh)
PL (1) PL185603B1 (sh)
PT (1) PT843661E (sh)
RO (1) RO120134B1 (sh)
RS (1) RS49521B (sh)
RU (1) RU2140910C1 (sh)
SA (1) SA96170171B1 (sh)
SK (1) SK284209B6 (sh)
TN (1) TNSN96104A1 (sh)
TR (1) TR199800208T1 (sh)
TW (1) TW495502B (sh)
UA (1) UA59341C2 (sh)
WO (1) WO1997007098A1 (sh)
ZA (1) ZA966760B (sh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701282A (es) * 1994-08-18 1997-05-31 Pfizer Fenoles neuroprotectores.
DK0843661T3 (da) * 1995-08-11 2002-07-22 Pfizer (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU3676100A (en) * 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27701A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
YU27801A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
MXPA03001472A (es) * 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
BRPI0213393B8 (pt) 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
CA2628074C (en) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
JP5383484B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 環式基で置換されたアミノジヒドロチアジン誘導体
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
RU2017107558A (ru) 2014-09-15 2018-10-18 Руджен Холдингс (Кайман) Лимитед Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b
WO2016049048A1 (en) * 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
KR102613179B1 (ko) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK279476B6 (sk) * 1989-05-17 1998-11-04 Pfizer Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
MX9701282A (es) * 1994-08-18 1997-05-31 Pfizer Fenoles neuroprotectores.
DK0843661T3 (da) * 1995-08-11 2002-07-22 Pfizer (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat

Also Published As

Publication number Publication date
AU5908496A (en) 1997-03-12
NO310458B1 (no) 2001-07-09
DK0843661T3 (da) 2002-07-22
JP3099072B2 (ja) 2000-10-16
EP0843661B1 (en) 2002-03-27
IL122649A0 (en) 1998-08-16
TNSN96104A1 (fr) 2005-03-15
IS4643A (is) 1997-12-30
CO4750830A1 (es) 1999-03-31
WO1997007098A1 (en) 1997-02-27
ATE215072T1 (de) 2002-04-15
HRP960372B1 (en) 2003-04-30
RS49521B (sr) 2006-10-27
KR100291882B1 (ko) 2001-10-26
CN1615861A (zh) 2005-05-18
CA2228752A1 (en) 1997-02-27
IL122649A (en) 2001-08-26
CN1198739A (zh) 1998-11-11
HRP960372A2 (en) 1998-04-30
IS1945B (is) 2004-08-13
ES2170857T3 (es) 2002-08-16
EP0843661A1 (en) 1998-05-27
DE69620191D1 (de) 2002-05-02
AU710984B2 (en) 1999-10-07
HUP9802862A2 (hu) 1999-04-28
RO120134B1 (ro) 2005-09-30
PL325050A1 (en) 1998-07-06
AP755A (en) 1999-08-02
JPH10510552A (ja) 1998-10-13
BR9610766A (pt) 1999-07-13
AP9600856A0 (en) 1996-10-31
DZ2083A1 (fr) 2002-10-23
PL185603B1 (pl) 2003-06-30
ZA966760B (en) 1998-02-09
BG63678B1 (bg) 2002-09-30
MA23957A1 (fr) 1997-04-01
GT199600051A (es) 1997-12-26
DE69620191T2 (de) 2002-07-18
PT843661E (pt) 2002-07-31
SK16698A3 (en) 1999-06-11
HUP9802862A3 (en) 1999-05-28
RU2140910C1 (ru) 1999-11-10
PE4898A1 (es) 1998-03-16
MX9801149A (es) 1998-05-31
TW495502B (en) 2002-07-21
US6008233A (en) 1999-12-28
KR19990036321A (ko) 1999-05-25
NO980574D0 (no) 1998-02-10
TR199800208T1 (sh) 1998-05-21
CZ296236B6 (cs) 2006-02-15
NZ309134A (en) 1999-09-29
SA96170171B1 (ar) 2006-05-20
NO980574L (no) 1998-02-10
UA59341C2 (uk) 2003-09-15
CA2228752C (en) 2002-12-10
AR004676A1 (es) 1999-03-10
OA10664A (en) 2000-11-06
SK284209B6 (en) 2004-11-03
BG102289A (en) 1998-09-30
CZ39098A3 (cs) 1999-02-17

Similar Documents

Publication Publication Date Title
YU46196A (sh) (1s,2s)-1-(4-hidroksifenil)-2-(4-dihidroksi-4-fenilpiperidin 1-il)-1-propanol metansul-fonat trihidrat
NO970161D0 (no) Triazolforbindelser og anvendelse derav
PT771197E (pt) Utilizacao de compostos heterociclicos como ligantes de dopamina-d 3
BG64475B1 (bg) Ципразидонови соли
IL114599A (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containg them
HUT74992A (en) Use of serotonin antagonist indol derivatives for producing pharmaceutical compositions using for treating fibromyalgia
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
EA199900559A1 (ru) Замещенные, азотсодержащие гетероциклы в качестве ингибиторов протеинкиназы p38
ME00901B (me) Mezilat trihidrat 5-(2-(4-(1 ,2-benzizotiazol-3-il)-1-piperazinil)-etil)-6-hlor0-1,3-dihidr0-2h-indol-2-ona
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
BG105256A (en) Muscarinic agonists and antagonists
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
NO20005668L (no) Forbindelser med veksthormonfrigjörende egenskaper
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
NZ331683A (en) New indole and indazole compounds, a process for their preparation and pharmaceutical compositions containing them
FR2742048B1 (fr) Utilisation de l'alpha-cyano-beta, beta-diphenylacrylate de 2-ethylhexyle pour ameliorer la stabilite de compositions cosmetiques contenant le p-methyl-benzylidene camphre en association avec un derive de dibenzoylmethane
EA200100098A1 (ru) Соли пароксетина
DE69528288D1 (de) Indolderivate zur behandlung von migräne
FR2749846B1 (fr) Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
BR9507848A (pt) Composição farmcéutica contendo espiramicina eventualmente em associação com o metronizadol